



Available online on 15.1.2020 at <http://ujpr.org>
Universal Journal of Pharmaceutical Research
 An International Peer Reviewed Journal



Open access to Pharmaceutical research
 This is an open access article distributed under the terms of the Creative Commons Attribution-Non
 Commercial Share Alike 4.0 License which permits unrestricted non commercial use,
 provided the original work is properly cited

Volume 4, Issue 6, 2019

Open Access

RESEARCH ARTICLE

EVALUATION OF CARBAPENEM USE AMONG PATIENTS AT INTENSIVE CARE UNIT (ICU) IN SANA'A, YEMEN

Ali Alyahawi¹, Gamil Alrubaiee², Ali Alkaf³

¹Department of Pharmacy, Al-Razi University, Yemen.

²Department of Applied Medical Sciences, Al-Razi University, Yemen.

³Faculty of Pharmacy, Sana'a University, Yemen.

ABSTRACT

Objective: Drug Utilization Evaluation (DUE) studies are designed to evaluate and improve the rational use of medications. In this study, DUE has focused on drugs used in high risk patients such as critically ill cases. Carbapenems are beta-lactam type antibiotics with broad-spectrum of activity which cover gram-positive, gram-negative and anaerobic bacteria. The heavy use of carbapenems (imipenem or meropenem) could increase the risk of multi-drug resistant (MDR) pathogens. This study was a prospective and cross sectional study performed at intensive care unit (ICU) of Al-Matwakel hospital in Sana'a, Yemen.

Methods: The study was conducted from September 2018 to March 2019. All of the patients were on imipenem or meropenem as an empiric treatment or based upon microbiology culture results included in the study. Total of 80 patients at ICU were evaluated.

Results: The results of the study showed that empiric therapy was in most cases (91.25%; $P < 0.001$). In addition; about 36.3% of the patients required dosage adjustment according to glomerular filtration rate (GFR) stages. Also according to GFR calculation, 43.8% of the patients were in stage 3. In the present study, the frequency of therapeutic duplication of ceftriaxone with carbapenem was reported in 38 patients. The major drug-drug interactions were observed with tramadol-imipenem, tramadol-meropenem, and amlodipine-simvastatin.

Conclusion: The result of the study showed that empiric therapy was unjustified in most cases (91.25%). In addition, about 36.3% of the patients required dosage adjustment according to GFR stages. According to GFR calculation, 43.8% of the patients were in stage 3. In the present study, the frequency of therapeutic duplication and drug-drug interactions were observed.

Keywords: Carbapenem, empirical, GFR, imipenem, MDR, meropenem.

Article Info: Received 2 November 2019; Revised 11 December; Accepted 7 January, Available online 15 January 2020



Cite this article-

Alyahawi A, Alrubaiee G, Alkaf A. Evaluation of Carbapenem use among patients at Intensive Care Unit (ICU) in Sana'a, Yemen. Universal Journal of Pharmaceutical Research 2019; 4(6):30-34.

DOI: <https://doi.org/10.22270/ujpr.v4i6.333>

Address for Correspondence:

Dr. Ali Alyahawi, Department of Pharmacy, Al-Razi University, Yemen. Tel: 00967-775957401, E-mail: alyahawipharm@yahoo.com

INTRODUCTION

One of the most important elements in patient care process is to evaluate the appropriateness of medication use. Medications review studies are aimed to evaluate and improve the rational use of drugs. They have mostly focused on drugs with higher cost, higher dispensing, relatively narrow therapeutic margin and also broad spectrum antibiotics. They also focus on medications prescribed in specialized populations such as elderly, critically ill, post-surgical and cancer patients¹. Carbapenem (imipenem/cilastatin and meropenem) drugs are beta-lactam type antibiotics with a broad spectrum of activity and coverage of Gram-positive and Gram-negative aerobic and anaerobic bacteria. Imipenem/cilastatin and meropenem use have increased as a result of high resistant rates to other antibiotics². Like other broad spectrum antibiotics, carbapenems are prescribed as a

part of empiric therapy in most serious hospitalised infections. Imipenem is a semisynthetic carbapenem co-administrated with cilastatin, to prevent renal metabolism of imipenem by dehydropeptidase I (DHP I). In contrast, this co-administration with the renal dehydropeptidase inhibitor, cilastatin is not necessary with meropenem, because this agent is not hydrolyzed by DHP I¹. The incidence of imipenem/cilastatin and meropenem resistance is increasing. One of the reasons could be the heavy use of these broad spectrum antibiotics in hospitalized patients including Intensive Care Units (ICUs)³. Improving the ICU environment involves education of critical care staff regarding the rational use of these drugs¹. According to a study conducted in Sana'a, Yemen by Alyahawi et al.⁴, the resistant rate of meropenem based on culture results was seen in 25.3% of all collected isolates. In this

study, utilization of these antibiotics in critically ill patients was reviewed.

METHODS

The study was performed in ICU at a private hospital in Sana'a, Yemen. All the patients on carbapenem drugs from September, 2018 to March, 2019 were included. A total of 80 folders of the patients on carbapenem drugs were collected from ICU at the mentioned study period. The study protocol was approved by the institutional ethical committee. The data was analyzed in order to identify dosage adjustment according GFR stages, carbapenem selection according to culture results or empirical therapy, major and moderate drug-drug interactions and antibiotic used in combination with carbapenem. Statistical analysis was done by SPSS software version 21.0 by using Pearson's Chi-square test. Categorical variables were expressed as percentages. P-value of less than 0.05 was considered significant.

RESULTS

Total of 80 patients at ICU were evaluated. The results of the study showed that 78.8% of the study sample was men and 21.3% were women. Also 43.8 of the study sample were aged ≥ 60 years old. In the present study, 80% of the patients were on meropenem and 20% of total patients on imipenem drug. According to the glomerular filtration rate (GFR) classification, 43.8% of patients had chronic kidney diseases (CKD) stage 3.

Table 1: Distribution of the study variables.

Variable	Frequency	%
Gender		
M	63	78.8
F	17	21.3
Age		
0-19	4	5
20-39	21	26.3
40-59	20	25
≥ 60	35	43.8
Imipenem	16	20
Meropenem	64	80
CKD		
1	12	15.0
2	11	13.8
3	35	43.8
Stage		
4	19	23.8
5	3	3.8

From the study findings, 36 of patients with chest infection (45%) were on imipenem/cilastatin or meropenem, followed by patients with sepsis (25%). According to glomerular filtration rate, there was 36.3% of carbapenem drugs (imipenem/cilastatin or meropenem) were needed dosage adjustment according to GFR stages. In addition, one carbapenem drug is not recommended by evidence used for patient. However, 8.8% of carbapenem drugs were used in low doses (Table 3). Table 4 showed the frequency of moderate drug-drug interactions in the present study. According to the drugs.com and Medscape, the frequency of moderate drug-drug interactions between all the patients' drugs was observed in 11 types. Detailed comments were reported in Table 4.

The frequency of major drug-drug interactions was demonstrated in Table 5. According to the drugs.com and Medscape, the frequency of major drug-drug interactions between all the patients' drugs was observed in three patients. Detailed major drug-drug interactions were reported in Table 5. In this study, there were 91.3% of patients on carbapenem drugs as empirical therapy ($P < 0.001$). However, 8.8% of patients used carbapenem drugs according to culture results. Figure 1 showed the percentage of antibiotics used before carbapenem administration for the study sample. Carbapenem drugs were administered in 75% of the patients as the first line. In contrast, 25% of patients used other antibiotics before carbapenem administration.

Table 2: Distribution of Carbapenem drugs used according to diagnosis.

Variable	Carbapenem used		Total
	Imipenem/ cilastatin	Meropenem	
Diagnosis	Brain Infection	2	3
	Chest Infection	27	36 (45%)
	CSF Infection	1	1
	Head Infection	1	1
	Meningitis	6	7
	Osteomyelitis	5	5
	SBP	1	1
	Sepsis	18	20 (25%)
	UTI	3	6
	Total	64	80

The review of the patients' drugs showed different drugs related problems. According to the study findings, the frequency of therapeutics duplication with carbapenem drugs was in 41 (51.3%) of patients. Moreover, the therapeutic duplication of ceftriaxone with carbapenem drugs was in 38 (92.7%) of these patients. In addition, one patient with urinary tract infection (UTI) was on moxifloxacin drug (less effective for UTI). Carbapenem drugs have a broad spectrum of activity, so most other antibiotics are unnecessary as combination to carbapenem (Table 7).

Table 3: Dosage adjustment according to GFR stages.

Variable	Frequency	%
Need dosage adjustment	29	36.3
Not need dosage adjustment	43	53.8
Low dose	7	8.8
Not recommended	1	1.3
Total	80	100.0

DISCUSSION

Applying standard treatment guidelines with training and supervision can guide physicians in the appropriate use of carbapenem drugs in hospital. Generally, most physicians use carbapenem drugs empirically for patients admitted to the ICU without the identification

the exact infection. They may be to think that all patients admitted to ICU have a severe infection⁵. Continuous drugs education by therapeutic committee and regular drug utilization evaluation programs could help in the rational medication use.




Figure 1: Antibiotics used before carbapenem.

The various clinical conditions and severity of infection for patient in ICU need the use of drugs from different classes⁶.

Table 4: Moderate Drug-Drug Interaction.

Type of drug-drug interaction	Frequency
Aspirin-Clopidogrel	3
Aspirin-Heparin	1
Azithromycin-Simvastatin	1
Captopril-Heparin	1
Ceftriaxone-Warfarin	1
Metronidazole-Phenytoin	2
Phenytoin-Insulin	1
Phenytoin-Nifedipine	1

The results of this study revealed that the majority of patients (43.8%) received carbapenem drugs were equal or above 60 years old. Similarly, a study conducted for evaluation of meropenem utilization in intensive care unit in Sudan by Sanhoury *et al.*,⁵ which found majority of patients, above 60 years old, received meropenem drug. In the current study, 91.3% of carbapenem drugs were prescribed without culture results; which means that these drugs were prescribed depending on physician' experience or on the severity of infection, but not according to isolated bacteria. This was not in agreement with a study conducted to evaluate the use of carbapenem in a French University hospital by Jary *et al.*, which found 60% of meropenem was prescribed empirically⁷.

Table 5: Major drug-drug interactions.

Type of Drug-drug interaction	Frequency
Amlodipine-Simvastatin	1
Tramadol-Imipenem	1
Tramadol-Meropenem	1

The irrational utilization of broad-spectrum antibiotics such as carbapenem can lead to the development of various resistant strains of bacteria. These contribute significantly to increase in the costs of health care and morbidity and mortality of patients⁸. So, monitoring and evaluation of antimicrobial agents are one of the significant recommended strategies to prevent, control resistance, and to improve the rational use of these

drugs⁵. The high prevalence of resistance in intensive care units (ICUs) is a key factor to increase the severity of the patient's illness, prolonged hospital stays, and the overuse of broad spectrum antibiotics. The selection of antimicrobial drugs for hospitalised infections is often driven by the patterns of hospital resistance and bacterial susceptibility surveillance. This can assist in clinical decisions regarding empirical antimicrobial therapy at each hospital⁹.

Table 6: Carbapenem selection according to culture or empirical therapy.

Variable	Frequency	%
Empirical Therapy	73	91.3
According to culture results	7	8.8
Total	80	100.0

The request for the overuse of antibiotics such as carbapenem drugs as well as noncompliance with infectious disease guidelines both contribute to the increase of bacterial resistance. In United States, 20% of resistance rates were reported to imipenem/cilastatin. It was regularly used for infection of high suspected *P. aeruginosa*¹⁰. The choice of appropriate dose of imipenem/cilastatin should be based on the location and severity of the infection, the susceptibility of the isolated pathogen(s), and the renal function of the patient. Adult patients with impaired renal function, as defined by creatinine clearance (CrCl) < 70 ml/min/1.73m², require dosage adjustment¹¹. According to results of current study, there was 36.3% of carbapenems (imipenem/cilastatin and meropenem) were required dosage adjustment according to GFR stages. This is similar to the results by a study conducted in Iran by Shiva *et al.*,¹² which found that the dosage of imipenem was inappropriate in 36% of patients, and the dosage adjustment (when needed) was either not done or done inappropriately in 64.3% of patients. Shiva *et al.*, also evaluated the utilization of imipenem/cilastatin in an educational hospital in Iran and found that there was a high empirical prescription of imipenem/cilastatin without considering culture and antimicrobial susceptibility results, and they observed there was a lack of attention to dosage adjustments in patients with renal insufficiency¹². Furthermore, in another study conducted by Sakhaian *et al.*, reported that the dosage adjustment of imipenem/cilastatin was not prescribed appropriately at their institution, and the researchers concluded that there was a need to more education for the health care professionals regarding the carbapenem dosage adjustment and their adjustment depends on the weight and the renal function of the patient¹³. Disorders of central nervous system (CNS) and kidney insufficiency had high risk factors for seizure occurrence. Therefore, the patients who received imipenem/cilastatin at higher than recommended doses had an increased risk of seizures, particularly in patients with kidney insufficiency¹⁴. Some studies found that the high consumption of carbapenems drugs was attributed for the prevalence of carbapenem-resistant Gram-negative bacteria¹⁵. In March 2017, the National Health and Family Planning

Commission (NHFPC) launched a special stewardship in clinical use of carbapenems¹⁶. According to the evaluation of drug-drug interactions in the present study, the major drug-drug interactions between all the patients' drugs were observed in three patients (Table 5). Co-administration with amlodipine may significantly increase the plasma concentrations of simvastatin and its active metabolite, simvastatin acid, and potentiate the risk of statin-induced myopathy. The proposed mechanism is amlodipine inhibition of simvastatin metabolism via intestinal and hepatic CYP450 3A4. Limit simvastatin dose to no more than 20 mg/day when used concurrently. In addition, the risk of seizures may be increased during co administration of tramadol with any substance that can reduce the seizure threshold, such as carbapenems (imipenem/cilastatin or meropenem). These agents are

often individually epileptogenic and may have additive effects when combined^{17,18}. The evaluation of patients' drugs showed the frequency of therapeutics duplication with carbapenem drugs (beta-lactam antibiotics) was in 41 (51.3%) of patients. In addition, the therapeutic duplication of ceftriaxone with carbapenem drugs was seen in 38 (92.7%) of these patients. Furthermore, carbapenem drugs have a broad spectrum of activity, so most other antibiotics are unnecessary as combination to carbapenem drugs such as levofloxacin and moxifloxacin. In this study, one patient with urinary tract infection (UTI) was on moxifloxacin drug. Not all fluoroquinolones can be used for urinary tract infections based on their pharmacokinetic profiles. Moxifloxacin achieve considerably lower concentrations in the urine than other quinolones and are not approved for this indication¹⁹.

Table 7: Distribution of other antibiotics use in combination with Carbapenem according to diagnosis.

Type of Antibiotic	Chest Infection	Head Infection	Meningitis	Osteomyelitis	Sepsis	UTI
Amoxicillin-Clavulanic Acid	1	D	0	0	0	0
Azithromycin	1	0	0	0	0	0
Cefepime	0	0	0	0	1	D
Ceftriaxone	8	D	0	3	D	1
Cefuroxime	1	D	0	0	0	0
Ciprofloxacin	1	0	0	0	0	0
Doxycycline-Ceftriaxone	0	0	0	0	1	D
Levofloxacin	1	0	0	0	0	0
Levofloxacin-Metronidazole	1	0	0	0	0	0
Linezolid	0	0	0	0	1	0
Metronidazole	2	0	1	2	2	1
Metronidazole-Ceftriaxone	4	D	0	1	D	1
Metronidazole-Ciprofloxacin	1	0	0	0	0	0
Metronidazole-Moxifloxacin	0	0	0	1	0	0
Moxifloxacin	3	0	0	0	3	1
Moxifloxacin-Ceftriaxone	8	D	0	0	2	D
Moxifloxacin-Metronidazole	0	0	0	0	1	0
Vancomycin	1	1	1	0	0	0
Vancomycin-Ampicillin	0	0	1	D	0	0
Vancomycin-Ceftriaxone	0	0	1	D	0	0
Vancomycin-Levofloxacin	0	0	0	1	0	0

D: Therapeutic Duplication; N: Not Recommended

In the current study, carbapenem drugs were administered in 75% of the patients as the first line. Interestingly, the prior use of antibiotics with broad-spectrum coverage, such as carbapenem drugs, was significantly associated with the acquisition of resistance²⁰. Carbapenem drugs should be reserved for the treatment of infections due to MDR pathogens²¹.

CONCLUSION

The study results showed that empiric therapy was prescribed in most cases (91.25%). In addition, about 36.3% of the patients required dosage adjustment according to GFR stages. Dosage adjustment, however, was not done as appropriate, mainly in patients who did not have a stable GFR. The need for interventional actions on carbapenem use is essential in the various units of the hospital. In the present study, the frequency of therapeutic duplication and drug-drug interactions were observed. More stringent controls and the implementation of stewardship principles are necessary to reduce the inappropriate use of carbapenem drugs.

AUTHOR'S CONTRIBUTION

The manuscript was carried out, written, and approved in collaboration with all authors.

ACKNOWLEDGEMENTS

The authors extend their thanks and appreciation to the Al-Razi University, Yemen to provide necessary facilities for this work.

COMPETING INTERESTS

The authors declare that they have no competing interests.

REFERENCES

- Mahini S, Hayatshahi A, Torkamandi H, Gholami K, Javadi MR. Carbapenem utilization in critically ill patients. *J Pharm Care* 2013; 1(4): 141-144.
<https://doi.org/10.1097/QCO.0000000000000622>
- Hawkey PM, Jones AM. The changing epidemiology of resistance. *J Antimicrob Chemother* 2009; 64(suppl 1):i3-10.
<https://doi.org/10.1093/jac/dkp256>

3. Akinci E, Colpan A, Bodur H, Balaban N, Erbay A. Risk factors for ICU-acquired imipenem resistant gram-negative bacterial infections. *J Hosp Infect* 2005; 59:317. <https://doi.org/10.1016/j.jhin.2004.09.030>
4. Alyahawi A, Alkaf A, Alnamer R, Alnosary T. Study of resistance for recently marketed carbapenem drug among hospitalised patients in Sana'a, Yemen. *Universal J Pharm Res* 2018; 3(5):58-62. <https://orcid.org/0000-0002-2724-9127>
5. Sanhoury OM, Eldalo AS. Evaluation of meropenem utilization in intensive care unit in Sudan. *Int J Clin Pharmacol Pharmacother* 2016; 1: 106. <https://doi.org/10.15344/2456-3501/2016/106>
6. Farooq JA, Ajaz M, Pandita KK, Rehana KMS, Yattoo GH, *et al.* Drug utilization at SKIMS-a tertiary care hospital. *JK-Practitioner* 2013; 18: 35-40. PMID: 25284928
7. Jary F, Kaiser JD, Henon T, Leroy J, Patry I, *et al.* Appropriate use of carbapenems in the Besançon university hospital. *Med Mal Infect* 2012; 42: 510-516. <https://doi.org/10.1016/j.medmal.2012.07.004>
8. Pulcini C, Pradier C, Samat-Long C, Hyvernât H, Bernardin G, *et al.* Factors associated with adherence to infectious diseases advice in two intensive care units. *J Antimicrob Chemother* 2006; 57: 546-550. <https://doi.org/10.1093/jac/dki483>
9. Gaynes R. Antibiotic resistance in ICU's: a multifaceted problem requiring a multifaceted solution. *Infect Control Hosp Epidemiol* 1995; 16:328-30. <https://doi.org/10.2307/30141062>
10. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. *Am J Infect Control*. 2004; 32:470. <https://doi.org/10.1016/S0196655304005425>
11. Kabbara, *et al.* Evaluation of imipenem/cilastatin in a tertiary care hospital. *Infect Drug Res* 2015:8.
12. Shiva A, Salehifar E, Amini M, *et al.* Drug utilization evaluation of imipenem in an educational hospital in Mazandaran Province. *J Pharm Sci* 2014; 20(1):12–17. PMID: 24250684
13. Sakhaian E, Hadjibabaie M, Gholami K, *et al.* Drug utilization evaluation of imipenem in patients undergoing bone marrow transplantation. *Int J Hematol Oncol Stem Cell Res* 2009; 3(2):10–13. <https://doi.org/10.2147/IDR.S78633>
14. Calandra G, Lydick E, Carrigan J, *et al.* Factors predisposing to seizures in seriously ill, infected patients receiving antibiotics: experience with imipenem/cilastatin. *Am J Med*. 1988; 84:911–918. [https://doi.org/10.1016/0002-9343\(88\)90071-x](https://doi.org/10.1016/0002-9343(88)90071-x)
15. Zhang, *et al.* Antimicrobial Resistance and Infection Control (2019) 8:5. <https://doi.org/10.3201/eid0702.010206>
16. National Health and Family Planning Commission of the People's Republic of China. Notice regarding to further strengthen the use of antibiotics and reduce antibiotic resistance. <http://www.nhfpc.gov.cn/zyygj/s7659/201703/d2f580480cef4ab1b976542b550f36cf.shtml>. <https://doi.org/10.1186/s13756-018-0449-3>
17. Edwards SJ, Emmas CE, Campbell HE. Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infections. *Curr Med Res Opin* 2005; 21(5): 785–94. <https://doi.org/10.1185/030079905X46223>
18. Birnbaum J, Kahan FM, Kropp H, MacDonald JS. Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin. *American J Med* 1985; 78 (6A): 3–21. [https://doi.org/10.1016/0002-9343\(85\)90097-x](https://doi.org/10.1016/0002-9343(85)90097-x)
19. Jancel T, Dudas V. Management of uncomplicated urinary tract infections. *West J Med* 2002; 176:51-5. <https://doi.org/10.1136/ewjm.176.1.51>
20. Lepelletier D, Cady A, Caroff N, Marraillac J, Reynaud A, Lucet JC, *et al.* Imipenem-resistant *Pseudomonas aeruginosa* gastrointestinal carriage among hospitalized patients: risk factors and resistance mechanisms. *Diagn Microbiol Infect Dis* 2010; 66(1):1-6. <https://doi.org/10.1016/j.diagmicrobio.2009.08.014>
21. Philippine, 2016. Philippine Clinical Practice Guidelines. <https://www.pcp.org.ph/index.php/latest-news-announcements/899-clinical-practice-guidelines>. <https://doi.org/10.7603/s40602-016-0003-6>